GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (STU:7F0) » Definitions » EV-to-EBITDA

Fulgent Genetics (STU:7F0) EV-to-EBITDA : -5.08 (As of Dec. 14, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Fulgent Genetics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Fulgent Genetics's enterprise value is €377.0 Mil. Fulgent Genetics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 was €-74.3 Mil. Therefore, Fulgent Genetics's EV-to-EBITDA for today is -5.08.

The historical rank and industry rank for Fulgent Genetics's EV-to-EBITDA or its related term are showing as below:

STU:7F0' s EV-to-EBITDA Range Over the Past 10 Years
Min: -170.44   Med: 1.72   Max: 270.18
Current: -4.9

During the past 10 years, the highest EV-to-EBITDA of Fulgent Genetics was 270.18. The lowest was -170.44. And the median was 1.72.

STU:7F0's EV-to-EBITDA is ranked worse than
100% of 115 companies
in the Medical Diagnostics & Research industry
Industry Median: 16.24 vs STU:7F0: -4.90

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-12-14), Fulgent Genetics's stock price is €18.20. Fulgent Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 was €-5.058. Therefore, Fulgent Genetics's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


Fulgent Genetics EV-to-EBITDA Historical Data

The historical data trend for Fulgent Genetics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics EV-to-EBITDA Chart

Fulgent Genetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 149.81 4.04 3.80 1.83 -9.06

Fulgent Genetics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.61 -9.06 -6.31 -5.28 -5.63

Competitive Comparison of Fulgent Genetics's EV-to-EBITDA

For the Diagnostics & Research subindustry, Fulgent Genetics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's EV-to-EBITDA falls into.



Fulgent Genetics EV-to-EBITDA Calculation

Fulgent Genetics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=377.038/-74.26
=-5.08

Fulgent Genetics's current Enterprise Value is €377.0 Mil.
Fulgent Genetics's EBITDA for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-74.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulgent Genetics  (STU:7F0) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Fulgent Genetics's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=18.20/-5.058
=At Loss

Fulgent Genetics's share price for today is €18.20.
Fulgent Genetics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.058.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


Fulgent Genetics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics Business Description

Traded in Other Exchanges
Address
4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Fulgent Genetics Headlines

No Headlines